Achieve Life Sciences
ACHV
31 hedge funds and large institutions have $16.6M invested in Achieve Life Sciences in 2023 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 12 increasing their positions, 6 reducing their positions, and 5 closing their positions.
453% more call options, than puts
Call options by funds: $2.32M | Put options by funds: $420K
239% more capital invested
Capital invested by funds: $4.9M → $16.6M (+$11.7M)
100% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 6
60% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 5
11% more funds holding
Funds holding: 28 → 31 (+3)
6.82% less ownership
Funds ownership: 20.59% → 13.78% (-6.8%)
Top Buyers
| 1 |
IC
Ikarian Capital
Dallas,
Texas
|
+$830K |
| 2 |
SC
Shay Capital
New York
|
+$665K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$452K |
| 4 |
Group One Trading
Chicago,
Illinois
|
+$418K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$376K |
Top Sellers
| 1 |
PCM
Perkins Capital Management
Wayzata,
Minnesota
|
-$384K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$229K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$98.6K |
| 4 |
Millennium Management
New York
|
-$75K |
| 5 |
CC
Clearline Capital
New York
|
-$66.5K |
ACHV Hedge Fund Activity: Q1 2023 in Review
31 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Achieve Life Sciences (ACHV) for Q1 2023, worth a combined $16.6M — up 239% from $4.9M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new ACHV positions and 5 closed out — a net gain of 3 holders — while 12 added to existing stakes and 6 trimmed.
The largest buyer was Ikarian Capital, opening a new position worth an estimated $830K. The largest seller was Perkins Capital Management, cutting an estimated $384K.
- 31 institutional investors held Achieve Life Sciences (ACHV) as of Q1 2023, up from 28 in Q4 2022.
- Funds reported $16.6M of Achieve Life Sciences stock for Q1 2023, up 239% quarter-over-quarter.
- 8 funds opened new Achieve Life Sciences positions in Q1 2023 and 5 closed out, a net change of +3 holders.
- The largest Achieve Life Sciences buyer in Q1 2023 was Ikarian Capital, an estimated $830K added.
- The largest Achieve Life Sciences seller in Q1 2023 was Perkins Capital Management, an estimated $384K sold.
Based on aggregated 13F filings for Q1 2023.